Problem
This is an excerpt from Applied Clinical Trials, 2020 Vision: Fulfilling the Future of Clinical Research. One point is that "the risk lies at the source of the information." What does this mean as a regulatory professional? And, does the meantime of that change when you think about that from the perspective of an end user that is a recipient of a drug that was approved under a risk-based monitoring plan?